bi 836826
mAbexperimental
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 11, 2011 (NCT01296932)
Timeline
Indications
Mechanism of action
- Leukocyte antigen CD37INHIBITOR
Leukocyte antigen CD37 inhibitor
- Leukocyte antigen CD37Supplementation
CD37 supplementation
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- NCATSLB090AB8DB ↗
- ChEMBLCHEMBL4594531 ↗
Also known as
- bi 836826
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03343678 | Phase 1 | Jan 17, 2018 | Boehringer Ingelheim |
| NCT02759016 | Phase 1 | Jun 23, 2016 | Boehringer Ingelheim |
| NCT02624492 | Phase 2 | Jan 28, 2016 | Boehringer Ingelheim |
| NCT02538614 | Phase 1 | Dec 29, 2015 | Boehringer Ingelheim, Gilead Sciences |
| NCT01403948 | Phase 1 | Aug 1, 2011 | Boehringer Ingelheim |
| NCT01296932 | Phase 1 | Feb 11, 2011 | Boehringer Ingelheim |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 6 | 5 | 2 | 2011 |
| Gilead Sciences | For profit | 1 | 1 | 1 | 2015 |
2 organizations
Page 1 / 1